These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33157214)

  • 1. Intranasal fosphenytoin: The promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs.
    Pires PC; Santos LT; Rodrigues M; Alves G; Santos AO
    Int J Pharm; 2021 Jan; 592():120040. PubMed ID: 33157214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nose-to-brain delivery of phenytoin and its hydrophilic prodrug fosphenytoin combined in a microemulsion - formulation development and in vivo pharmacokinetics.
    Pires PC; Fazendeiro AC; Rodrigues M; Alves G; Santos AO
    Eur J Pharm Sci; 2021 Sep; 164():105918. PubMed ID: 34174414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: Formulation development and in vitro characterization.
    Pires PC; Peixoto D; Teixeira I; Rodrigues M; Alves G; Santos AO
    Eur J Pharm Sci; 2020 Jan; 141():105099. PubMed ID: 31672614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method.
    Antunes Viegas D; Rodrigues M; Francisco J; Falcão A; Alves G; Santos AO
    Eur J Pharm Sci; 2016 Jun; 89():61-72. PubMed ID: 27106504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosphenytoin: a novel phenytoin prodrug.
    Boucher BA
    Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of fosphenytoin for the treatment of status epilepticus.
    Popławska M; Borowicz KK; Czuczwar SJ
    Expert Rev Neurother; 2015; 15(9):983-92. PubMed ID: 26289487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
    Fischer JH; Patel TV; Fischer PA
    Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of fosphenytoin: options for the management of seizures.
    Ramsay RE; DeToledo J
    Neurology; 1996 Jun; 46(6 Suppl 1):S17-9. PubMed ID: 8649609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosphenytoin (Cerebyx).
    Browne TR
    Clin Neuropharmacol; 1997 Feb; 20(1):1-12. PubMed ID: 9037568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and pharmacokinetics of fosphenytoin.
    Browne TR; Kugler AR; Eldon MA
    Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of fosphenytoin sodium.
    Fierro LS; Savulich DH; Benezra DA
    Am J Health Syst Pharm; 1996 Nov; 53(22):2707-12. PubMed ID: 8931812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosphenytoin.
    Eriksson K; Keränen T; Kälviäinen R
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):695-701. PubMed ID: 19473113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
    Knapp LE; Kugler AR
    J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosphenytoin use in children.
    Pellock JM
    Neurology; 1996 Jun; 46(6 Suppl 1):S14-6. PubMed ID: 8649608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosphenytoin.
    Luer MS
    Neurol Res; 1998 Mar; 20(2):178-82. PubMed ID: 9522355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
    Ogutu BR; Newton CR; Muchohi SN; Otieno GO; Edwards G; Watkins WM; Kokwaro GO
    Br J Clin Pharmacol; 2003 Jul; 56(1):112-9. PubMed ID: 12848783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.
    Higuchi K; Yamashita D; Kashihara Y; Kakara M; Hirota T; Hirakawa M; Ieiri I
    Ther Drug Monit; 2019 Oct; 41(5):674-680. PubMed ID: 31095070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin.
    Löscher W; Reissmüller E; Ebert U
    Epilepsy Res; 1998 Mar; 30(1):69-76. PubMed ID: 9551846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
    Ohno Y; Niwa T; Hirai K; Suzuki K; Yamada Y; Hayashi Y; Hayashi H; Suzuki A; Itoh Y
    Ther Drug Monit; 2018 Aug; 40(4):507-511. PubMed ID: 29683874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.